BPH: Combination therapy
Evolving optimal treatment goals include relieving bothersome symptoms, alteration of disease progression and prevention of complications associated with LUTS/BPH. 1
Efficacy of combination therapy vs monotherapy
The efficacy of dutasteride plus tamsulosin has been investigated in the CombAT study. 2
Participants in the trial were men aged ≥50 years (n=4844) with a clinical diagnosis of BPH and an IPSS of ≥12, prostate volume 30 cm3 total serum PSA 1.5 ng/mL, and Qmax >5 mL/s and 15 mL/s with a minimum voided volume of 125 mL. 2
Efficacy in symptom relief
Dutasteride co-prescribed with tamsulosin offers rapid symptom improvement starting as early as tamsulosin monotherapy. 2
Dutasteride co-prescribed with tamsulosin offers significantly superior and sustained symptoms improvement vs tamsulosin monotherapy from months 9-48. 2
Alteration of disease progression and prevention of complications
Dutasteride co-prescribed with tamsulosin offers significant reduction in prostate volume vs tamsulosin monotherapy at Month 48. 2
Dutasteride co-prescribed with tamsulosin reduced the risk of disease progression and complications vs tamsulosin monotherapy at Month 48. 2
ARR, Absolute Risk Reduction; CI, confidence interval; RRR, Relative Risk Reduction.
References:
- McVary T, et al. AUA Guidelines on BPH 2010; reviewed and validity confirmed in 2014. Available at: http://www.auanet.org/documents/education/clinical-guidance/Benign-Prostatic_hyperplasia.pdf. Accessed March 2020.
- Roehrborn CG, et al. Eur Urol 2010;57:123–131.
Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.